重症成人患者基于不同药动学/药效学目标的庆大霉素剂量推荐:一种重新定义的方法
本研究利用21项已发表研究的重症患者药动学与人口学数据构建一室药动学模型,采用蒙特卡洛模拟评估庆大霉素每日一次给药5-10 mg/kg的疗效达标概率(PTA)及肾毒性风险。结果显示,当MIC<0.5 mg/L时,7 mg/kg/day可使两个疗效目标达标率均超过90%;当MIC升至1 mg/L时,8 mg/kg/day可达到PK/PD及安全目标;对于MIC≥2 mg/L的病原体,所研究的剂量均无法达到疗效目标。作者结论认为,对于MIC≤1 mg/L的病原体,推荐重症患者庆大霉素初始剂量8 mg/kg/day,但强调临床验证至关重要。
要点
- 对于MIC<0.5 mg/L的病原体,庆大霉素7 mg/kg/day可使Cmax/MIC~8-10和AUC24h/MIC≥110两个疗效目标达标率均超过90%。
- 当MIC升至1 mg/L时,庆大霉素8 mg/kg/day可达到PK/PD及安全目标。
- 对于MIC≥2 mg/L的病原体,所研究的庆大霉素剂量(5-10 mg/kg)均不足以达到疗效目标。
- AUC24h>700 mg·h/L预测肾毒性风险较小,但采用Cmin>2 mg/L目标时肾毒性风险更大。
- 作者推荐对MIC≤1 mg/L的病原体,重症患者庆大霉素初始剂量为8 mg/kg/day,并强调需临床验证。
适用人群与场景
- 重症成人患者,感染前3天内
- 病原体MIC≤1 mg/L时考虑推荐剂量;MIC≥2 mg/L时所研究剂量均不足
诊断标准与关键阈值
- 疗效PK/PD目标:Cmax/MIC ~8-10 和 AUC24h/MIC ≥110
- 肾毒性预测阈值:AUC24h >700 mg·h/L 和 Cmin >2 mg/L
处置流程与药物剂量
- 庆大霉素每日一次给药(ODDG),剂量范围5-10 mg/kg,具体剂量根据MIC选择:MIC<0.5 mg/L时7 mg/kg/day可达两个疗效目标>90%;MIC 1 mg/L时8 mg/kg/day可达PK/PD及安全目标;MIC≥2 mg/L时无 studied 剂量足够。
研究设计与关键结果
- 研究类型:基于21项已发表研究的药动学与人口学数据构建一室药动学模型,采用蒙特卡洛模拟。
- 模拟剂量:庆大霉素每日一次5-10 mg/kg。
- 主要终点:疗效达标概率(PTA)针对Cmax/MIC~8-10和AUC24h/MIC≥110。
- 结果:MIC<0.5 mg/L时,7 mg/kg/day可使两个疗效目标PTA均>90%;MIC 1 mg/L时,8 mg/kg/day可达PK/PD及安全目标;MIC≥2 mg/L时,所研究剂量均未达到疗效目标。
- 肾毒性风险:AUC24h>700 mg·h/L预测风险较小,Cmin>2 mg/L目标时风险更大。
证据类型、等级与局限
- 证据类型:基于文献数据的药动学模型与蒙特卡洛模拟研究。
- 局限:作者结论强调临床验证至关重要(Clinical validation of our results is essential)。
对床旁实践的改变
- 作者认为,对于MIC≤1 mg/L的病原体,重症成人患者庆大霉素初始剂量可推荐为8 mg/kg/day(同时考虑Cmax/MIC~8-10和AUC24h/MIC≥110目标),但临床验证至关重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In addition to the maximum plasma concentration (Cmax) to the minimum inhibitory concentration (MIC) ratio, the 24-hour area under the concentration-time curve (AUC24h) to MIC has recently been suggested as pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy and safety in once-daily dosing of gentamicin (ODDG) in critically ill patients.
PURPOSE: This study aimed to predict the optimal effective dose and risk of nephrotoxicity for gentamicin in critically ill patients for two different PK/PD targets within the first 3 days of infection.
METHODS: The gathered pharmacokinetic and demographic data in critically ill patients from 21 previously published studies were used to build a one-compartment pharmacokinetic model. The Monte Carlo Simulation (MCS) method was conducted with the use of gentamicin once-daily dosing ranging from 5-10 mg/kg. The percentage target attainment (PTA) for efficacy, Cmax/MIC ~8-10 and AUC24h/MIC ≥110 targets, were studied. The AUC24h >700 mg⋅h/L and Cmin >2 mg/L were used to predict the risk of nephrotoxicity.
RESULTS: Gentamicin 7 mg/kg/day could achieve both efficacy targets for more than 90% when the MIC was <0.5 mg/L. When the MIC increased to 1 mg/L, gentamicin 8 mg/kg/day could reach the PK/PD and safety targets. However, for pathogens with MIC ≥2 mg/L, no studied gentamicin doses were sufficient to reach the efficacy target. The risk of nephrotoxicity using AUC24h >700 mg⋅h/L was small, but the risk was greater when applying a Cmin target >2 mg/L.
CONCLUSION: Considering both targets of Cmax/MIC ~8-10 and AUC24h/MIC ≥110, an initial gentamicin dose of 8 mg/kg/day should be recommended in critically ill patients for pathogens with MIC of ≤1 mg/L. Clinical validation of our results is essential.
参考来源
- Abbasi MY, Chaijamorn W, Wiwattanawongsa K, et al. Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach. Clin Pharmacol. 2023. PMID: 37427084. doi:10.2147/CPAA.S417298
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。